Johns Hopkins researchers have devised a protein "switch" that instructs cancer cells to produce their own anti-cancer medication. In lab tests, the researchers showed that these switches, working from inside the cells, can activate a powerful cell-killing drug when the device detects a marker linked to cancer...

The September issue of the journals Clinical Cancer Research and Cancer Research published OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announcement of new data from its Phase II clinical and a pre-clinical study of custirsen (OGX-011/TV-1011), a drug that inhibits the production of clusterin, which is a protein commonly over-produced in cancer cells and a cause of treatment failure...

Using a strategy based on treating cancer cells that carry a specific genetic signature hyper-expression of the protein Myc with therapy that affects the stability of the cell's DNA, more effective results can be achieved. This was discovered by Andreas Höglund in his dissertation to be publicly defended at Umeå University on September 9...